BioCentury
ARTICLE | Clinical News

MOGN, MethylGene begin MG98 Phase II

August 21, 2001 7:00 AM UTC

MGI Pharma (MOGN) and MethylGene (Montreal, Quebec) began a Canadian Phase II trial of the companies' MG98 DNA methyltransferase antisense inhibitor in up to 30 patients with advanced and/or metastati...